{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-070151","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.923440+00:00","generated_at":"2026-06-14T02:39:35.366478+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Marker Therapeutics treats first lymphoma patient in Phase 1 APOLLO trial of MT-601","bullets":["First patient dosed at 200 million cells; no treatment-related adverse events after 18 days.","Trial enrolls up to 30 patients across 8 U.S. sites for lymphoma patients relapsed after or ineligible for anti-CD19 CAR T therapy.","MT-601 targets six tumor antigens; prior TACTAL study showed durable responses with a five-antigen product.","Nonclinical data from May 2023 showed MT-601 inhibited lymphoma cells regardless of CD19 expression and overcame CAR T resistance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-070151","json":"https://secwatch.observer/filing/0001104659-23-070151.json","markdown":"https://secwatch.observer/filing/0001104659-23-070151.md","text":"https://secwatch.observer/filing/0001104659-23-070151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923070151/0001104659-23-070151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923070151/tm2317378d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:39:35.366478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}